Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
NAQUA (trichlormethiazide) is an oral thiazide diuretic approved in 1960 for the treatment of hypertension and edema. It works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting diuresis and reducing blood volume. Trichlormethiazide is among the earliest thiazide-class agents in the antihypertensive market.
NAQUA is an aging, legacy product approaching loss of exclusivity with minimal modern commercial infrastructure, indicating limited career growth and small team size.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NAQUA offers minimal career advancement opportunity; the product is a legacy agent with zero linked job openings and a declining market footprint. Roles on this team are typically maintenance-focused, offering limited exposure to modern drug development, innovation, or commercial upside.
Worked on NAQUA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.